Primorigen Biosciences Inc. of Madison has entered into an exclusive worldwide distribution agreement with STEMCELL Technologies, Inc., of Vancouver, B.C., Canada.
The agreement covers distribution of StemAdhere, a new cell adhesion product developed and manufactured by Primorigen that promotes stem cell growth and pluripotency — the ability to become any cell type. The product is designed as a tool to help researchers focused on reversing conditions such as diabetes, Alzheimer’s Disease and other degenerative diseases.
Under the agreement, StemAdhere will be sold by STEMCELL Technologies under Primorigen’s brand. Primorigen will continue to produce StemAdhere in its Madison, Wis., facilities, and STEMCELL Technologies will use its global sales network and market leadership in stem cell culture media to promote StemAdhere worldwide. STEMCELL Technologies will provide customer technical support, and both firms will cooperate on joint marketing efforts.
As a defined substrate for maintaining human pluripotent stem cell in their undifferentiated state, StemAdhere reduces variability of experimental results and eliminates cumbersome steps required for other matrices, addressing two key market needs.
STEMCELL Technologies Inc is a privately-owned biotechnology company that develops specialty cell culture media, cell separation products and ancillary reagents for life science research. Widely recognized as an international market leader in stem cell culture technologies. STEMCELL delivers more than 1,000 products to more than 70 countries worldwide.
Primorigen Biosciences Inc., is an emerging leader in developing innovative solutions for stem cell maintenance, proliferation, characterization and assay development. The company also is developing human stem cell-derived disease models for high-throughput, low-cost compound and toxicity screening, addressing a strong need in pharmaceutical drug discovery.
Contact Chuck Oehler at 608-441-8332 to learn more, or visit http://www.primorigen.com/